Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-11

Study Completion Date

2017-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

NCT03610464

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE4

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT06248229

Fatigue Attention Deficit Hyperactivity Disorder Attention Deficit Disorder

RECRUITING PHASE4

Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00507065

ADHD

COMPLETED PHASE3

NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD

NCT00557011

Attention Deficit Disorder With Hyperactivity

COMPLETED PHASE2

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

NCT00141063

ADHD

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover study to assess the efficacy and safety of dose Dyanavel XR in reducing signs and symptoms of ADHD compared with placebo in pediatric subjects ages 6 to 12 years with ADHD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover study

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

placebo-controlled

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Treatment

Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM

Group Type ACTIVE_COMPARATOR

amphetamine extended-release oral suspension, 2.5 mg/mL

Intervention Type DRUG

5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

Placebo extended-release oral suspension

Intervention Type DRUG

6, 7 or 8 mL PO

Placebo Treatment

Double blind placebo, 6, 7 or 8 mL po QAM

Group Type PLACEBO_COMPARATOR

amphetamine extended-release oral suspension, 2.5 mg/mL

Intervention Type DRUG

5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

Placebo extended-release oral suspension

Intervention Type DRUG

6, 7 or 8 mL PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

amphetamine extended-release oral suspension, 2.5 mg/mL

5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO

Intervention Type DRUG

Placebo extended-release oral suspension

6, 7 or 8 mL PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dyanavel XR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females aged 6 to 12 years at the time of screening, inclusive
2. Diagnosed with ADHD by a psychiatrist within 6 months of study enrolment or newly diagnosed with ADHD using the DSM-5 criteria for ADHD
3. An ADHD-RS-5 score at Screening ≥90th percentile for sex and age in at least one of the following categories:

1. Hyperactive-impulsive subscale,
2. Inattentive subscale, or
3. Total score. Subjects who do not meet this criteria at screening can have ADHD-RS-5 repeated at baseline, after washout of stimulant medication for a minimum of 24 hours prior to baseline.
4. In the clinical judgment of the Investigator, the subject must be in need of pharmacological treatment for ADHD.
5. Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at screening
6. Provide written informed consent (parent/guardian) and assent (child aged 10 - 12 years only) prior to participation in the study

Exclusion Criteria

1. Diagnosed with any DSM-5 active disorder (other than ADHD) with the exception of specific phobias, learning disorders, motor skills disorders, communication disorders, oppositional defiant disorder, elimination disorders, and sleep disorders
2. Known history of chronic medical illnesses including severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, known family history of sudden death
3. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment (liver function test results ≥ two times the upper limit of normal, blood urea nitrogen, or creatinine).
4. Clinically significant abnormal ECG or cardiac findings on physical examination (including the presence of a pathologic murmur)
5. Use of the following medications within 30 days of Baseline Visit:

* MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine, tranylcypromine)
* Tricyclic Antidepressants (e.g. Desipramine, protriptyline)
6. Use of the following medications within 3 days of Baseline Visit

* Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid)
* Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts)
7. Use of atomoxetine within 14 days of Baseline Visit
8. Planned use of prohibited drugs or agents from the Screening visit through the end of the study
9. Abnormal clinically significantly laboratory test value at screening that, in the opinion of the Investigator, would preclude study participation
10. Known history of allergy/hypersensitivity to amphetamine or any of the components of Dyanavel XR, or topical anaesthetics
11. Known history of lack of response to amphetamine
12. Parent or guardian's inability or unwillingness to follow directions of the Investigator or study research staff.
13. Any uncontrolled medical condition that in the opinion of the Investigator would preclude study participation
14. History of significant illness requiring hospitalization, or surgery requiring anaesthetics within 30 days of Baseline Visit

Minimum Eligible Age

6 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No